Chinese Medicinal Herb Growing in China: Market Size, Businesses & Forecast 2026

The Chinese Medicinal Herb Growing industry in China focuses on the structured cultivation, tending, and harvesting of traditional botanical components used in domestic and international healthcare regimens. Propelled by central policy mandates, the sector is modernizing through the establishment of regional clusters dedicated to authentic varieties to replace depleting wild resources. According to China's Ministry of Agriculture and Rural Affairs, the national planting area for traditional medicinal materials reached approximately 50 million mu (3.33 million hectares) by 2025 (Ministry of Agriculture and Rural Affairs, 2025), a capacity that has doubled over the preceding decade. The sector

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Chinese Medicinal Herb Growing in China industry cover?

This industry encompasses the agricultural cultivation, localized wild-tending, and preliminary post-harvest processing of plants used for traditional medicine. Activities include soil preparation, sowing, nurturing, and raw harvesting of roots, tubers, leaves, seeds, and bark, as well as essential washing and drying. Preliminarily processed herbs are classified legally as edible agricultural products before they are refined into medical decoctions or formulas.

• •Covers more than 200 highly commercialized medicinal plant species that exhibit industrial market demands exceeding 1,000 tons annually.
• •Differentiates basic raw harvesting and manual field drying from advanced secondary downstream extraction, chemical isolation, and patent manufacturing.
• •Primary production functions as a prerequisite foundational layer for the broader, highly regulated downstream domestic healthcare and pharmaceutical supply chain.

Who operates in the industry and how is it structured?

The structural composition of the market remains highly fragmented, though it is transitioning rapidly via vertical integration model frameworks. The upstream landscape comprises individual agricultural households, localized rural cooperatives, and specialized industrial planting bases managed directly by pharmaceutical conglomerates. Circulating raw materials flow through concentrated trade hubs before advancing to specialized processing enterprises.

• •Upstream distribution relies on 17 legal, specialized national Chinese medicinal material (CMM) markets that act as primary regional trade and pricing hubs.
• •Production is optimized geographically across seven major strategic regional clusters optimized for authentic ('Daodi') ecological varieties.
• •Regional supply variation exists, where certain provinces like Jilin feature fragmented smallholder networks while Beijing and Shandong operate integrated corporate bases.

What drives demand in the industry?

Industrial expansion is driven directly by systemic healthcare integration and an aging national demographic that intensifies the utilization of holistic therapies. Central state inclusion of traditional therapies into broader public health insurance frameworks structurally sustains high transaction volumes. Additionally, changing consumer habits regarding herbal beverages, health supplements, and daily preventative dietary choices expand the primary consumption base.

• •National demand supports care requirements for over 900 million patients utilizing traditional therapies annually across China's medical networks.
• •Herbal-based prescriptions consistently account for more than 65% of all traditional Chinese medicine medical treatments evaluated nationwide.
• •Downstream reliance is anchored by an infrastructure of thousands of hospitals, clinics, and over 3,000 operational traditional processing enterprises.

Who are the notable companies in the industry?

The corporate tier is characterized by крупный integrated pharmaceutical actors who manage dedicated upstream cultivation contracts to protect supply integrity. These entities invest directly in standardized cultivation fields to bypass quality variances common to independent open-market sourcing. Competition centers on securing certified geographic regions known historically for producing potent, high-quality strains.

• •China Traditional Chinese Medicine Holdings Co. Limited maintains expansive cultivation networks to supply its widespread downstream processing lines.
• •Yunnan Baiyao Group Co., Ltd. secures specialized domestic botanical inputs to sustain its flagship proprietary consumer and medical portfolios.
• •Beijing Tong Ren Tang Chinese Medicine Co. Ltd. represents one of the longest-standing corporate brands cultivating authentic medicinal ingredients.
• •Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. operates targeted regional cultivation networks to guarantee rare and premium raw inputs.

What are the recent trends and outlook?

The industry's trajectory involves a concerted pivot away from unmonitored wild harvesting toward structured, ecologically traceable field cultivation. Advancements in tracking software and regional mapping are being deployed to better align regional growing conditions with manufacturing hubs. Strategic state focus remains fixed on establishing specialized agricultural towns to foster durable, brand-protected herbal varieties.

• •A sharp depletion of wild botanical reserves has forced a shift where approximately 70% of historical strains are targeted for replacement by cultivated models.
• •The Ministry of Agriculture and Rural Affairs is actively building high-level, authentic regional production bases to optimize nationwide output yields.
• •Modern corporate facilities are increasingly utilizing digital traceability platforms to track herb lifecycles from seed selection to final harvest.

How is the industry regulated?

Regulatory frameworks are shifting toward mandatory compliance and uniform standard metrics to assure biochemical safety and quality stability. Primary agricultural operations are overseen jointly via agricultural, environmental, and medical product regulatory offices to restrict contamination risks. The primary standardizing baseline aims to eliminate chemical, pesticide, and heavy-metal variations at the farm level.

• •The framework is guided internationally and domestically by Good Agricultural Practice (GAP) guidelines for traditional herbal medicine trade.
• •Raw, unrefined yields are subject to the overarching consumer safety principles set forth by China's amended National Food Safety Law.
• •National Medical Products Administration (NMPA) oversight continuously enforces strict chemical and residue testing protocols across field suppliers.

Government, statistical and trade sources used for this Claight analysis.

• Ministry of Agriculture and Rural Affairs (MARA) Official Press Release 2025 ·
• National Medical Products Administration (NMPA) Compliance Reports ·
• National Bureau of Statistics (NBS) Economic Activity Classification (GB/T 4754-2017) ·
• China Association of Chinese Medicine Industry Datasets